These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 10787431)

  • 1. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
    Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
    J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.
    Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Bernier L; Mamer O; Davignon J
    J Lipid Res; 2002 Oct; 43(10):1680-7. PubMed ID: 12364552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
    Campos H; Perlov D; Khoo C; Sacks FM
    J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
    Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
    J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
    Breyer ED; Le NA; Li X; Martinson D; Brown WV
    J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.
    Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn JS
    J Lipid Res; 1999 Apr; 40(4):636-47. PubMed ID: 10191287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
    Dinkel RE; Barrett PH; Demant T; Parhofer KG
    Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.
    Cohn JS; Batal R; Tremblay M; Jacques H; Veilleux L; Rodriguez C; Mamer O; Davignon J
    J Lipid Res; 2003 Oct; 44(10):1976-83. PubMed ID: 12867543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
    Zheng C; Khoo C; Furtado J; Sacks FM
    Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
    Karpe F; Hellénius ML; Hamsten A
    Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
    Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
    J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.
    Cohn JS; Tremblay M; Batal R; Jacques H; Rodriguez C; Steiner G; Mamer O; Davignon J
    Atherosclerosis; 2004 Nov; 177(1):137-45. PubMed ID: 15488876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.
    Le NA; Gibson JC; Ginsberg HN
    J Lipid Res; 1988 May; 29(5):669-77. PubMed ID: 3411241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject.
    Huff MW; Evans AJ; Wolfe BM; Connelly PW; Maguire GF; Strong WL
    J Lipid Res; 1990 Mar; 31(3):385-96. PubMed ID: 2341805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.
    Ooi EM; Chan DT; Watts GF; Chan DC; Ng TW; Dogra GK; Irish AB; Barrett PH
    J Lipid Res; 2011 Apr; 52(4):794-800. PubMed ID: 21297177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.